Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence

被引:28
作者
Weiser, SD
Guzman, D
Riley, ED
Clark, R
Bangsberg, DR
机构
[1] Univ Calif San Francisco, San Francisco Gen Hosp, EPI Ctr, Div Infect Dis, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, San Francisco Gen Hosp, Posit Hlth Program, San Francisco, CA 94143 USA
来源
HIV CLINICAL TRIALS | 2004年 / 5卷 / 05期
关键词
adherence; highly active antiretroviral therapy; homeless; nonnucleoside reverse transcriptase inhibitors; protease inhibitors; viral load;
D O I
10.1310/LNHD-K1R7-HQP5-HJCQ
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Although evidence suggests that antiretroviral (ARV) regimens containing nonnucleoside reverse transcriptase inhibitors (NNRTIs) are superior to single-protease inhibitor (PI)-based regimens at suppressing viral load, it is unclear how much of the improved viral suppression is due to intrinsic drug potency versus higher levels of adherence to simpler regimens. We therefore examined adherence and viral suppression in NNRTI and single-PI regimens in a cohort of largely ARV-experienced participants by using objective measures of adherence. Method: Participants were recruited from the Research on Access to Care in the Homeless (REACH) Cohort and were included in the study if they were on single-PI-based or NNRTI-based highly active antiretroviral therapy (HAART) regimens for at least 3 months prior to study entry. Adherence was measured by unannounced pill counts at the participant's usual place of residence. The primary outcome was suppression of HIV viral RNA to <50 copies/mL. Results: Among 109 individuals who were followed for a median of 8.7 months, the odds of virologic suppression were approximately 8 times higher (p < .01) for participants on NNRTI-based regimens (n = 53) compared with those using single-PI-based regimens (n = 56) when controlling for adherence, as well as other potential confounders in a multivariable analysis. The only other independent predictors of viral suppression in multivariable modeling were ARV adherence (p < .01), CD4 nadir (p = .02), and continuous months on current regimen prior to the start of adherence monitoring (p < .01). There was no significant difference in adherence by unannounced pill counts in participants receiving NNRTI- versus single-PI-containing regimens. Conclusion: A higher proportion of individuals using NNRTI-based regimens had viral suppression when compared to those taking single-PI-containing regimens, and this association was not confounded by higher levels of adherence. These results suggest that improved viral suppression on NNRTI regimens compared to single-PI regimens is more closely associated with regimen potency than higher levels of adherence.
引用
收藏
页码:278 / 287
页数:10
相关论文
共 46 条
[1]   Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. [J].
Albrecht, MA ;
Bosch, RJ ;
Hammer, SM ;
Liou, SH ;
Kessler, H ;
Para, MF ;
Eron, J ;
Valdez, H ;
Dehlinger, M ;
Katzenstein, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :398-407
[2]  
ANTINORI A, 2002, 14 INT AIDS C JUL BA
[3]   Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring [J].
Arnsten, JH ;
Demas, PA ;
Farzadegan, H ;
Grant, RW ;
Gourevitch, MN ;
Chang, CJ ;
Buono, D ;
Eckholdt, H ;
Howard, AA ;
Schoenbaum, EE .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) :1417-1423
[4]   High levels of adherence do not prevent accumulation of HIV drug resistance mutations [J].
Bangsberg, DR ;
Charlebois, ED ;
Grant, RM ;
Holodniy, M ;
Deeks, SG ;
Perry, S ;
Conroy, KN ;
Clark, R ;
Guzman, D ;
Zolopa, A ;
Moss, A .
AIDS, 2003, 17 (13) :1925-1932
[5]   Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population [J].
Bangsberg, DR ;
Hecht, FM ;
Charlebois, ED ;
Zolopa, AR ;
Holodniy, M ;
Sheiner, L ;
Bamberger, JD ;
Chesney, MA ;
Moss, A .
AIDS, 2000, 14 (04) :357-366
[6]   A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy [J].
Bangsberg, DR ;
Bronstone, A ;
Hofman, R .
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2002, 14 (01) :3-15
[7]   Non-adherence to highly active antiretroviral therapy predicts progression to AIDS [J].
Bangsberg, DR ;
Perry, S ;
Charlebois, ED ;
Clark, RA ;
Roberston, M ;
Zolopa, AR ;
Moss, A .
AIDS, 2001, 15 (09) :1181-1183
[8]   Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides [J].
Barreiro, P ;
Soriano, V ;
Casas, E ;
González-Lahoz, J .
AIDS, 2002, 16 (02) :245-249
[9]   Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy [J].
Barreiro, P ;
Soriano, V ;
Blanco, F ;
Casimiro, C ;
de la Cruz, JJ ;
González-Lahoz, J .
AIDS, 2000, 14 (07) :807-812
[10]   Addressing the challenges of adherence [J].
Bartlett, JA .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 :S2-S10